Federal authorities have filed charges against two Indian nationals accused of operating a scheme to sell fake Ozempic within the United States. According to the charges, the individuals smuggled the counterfeit medication into the country from China. The illicit operation reportedly persisted even after the U.S. Food and Drug Administration (FDA) intervened by seizing a portion of the counterfeit supply in December 2023.

Following the seizure, the FDA issued a public warning to alert consumers and healthcare providers about the presence of counterfeit versions of the popular diabetes and weight-loss drug in the supply chain. Despite this official notice, the defendants allegedly continued their distribution efforts. The case highlights ongoing international challenges regarding the regulation of pharmaceutical supply chains and the rise of counterfeit medical products sold online. Authorities have not yet released full details regarding the total volume of counterfeit drugs distributed or the specific methods used to bypass customs and distribution regulations. The investigation remains active as officials work to track the source of the counterfeit goods and prevent further distribution of the fake medication.